CVS Health Corp.
CVS · NYSE
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | 322.47B | 54.50B | 7.95B | 4.31B | 3.29 |
| 2023 FY | 357.78B | 54.43B | 13.74B | 8.34B | 6.49 |
| 2024 FY | 372.81B | 51.40B | 8.52B | 4.61B | 3.66 |
| 2025 FY | 402.07B | 55.36B | 10.39B | 1.77B | 1.40 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 228.28B | 156.51B | 12.95B | 70.73B | 71.47B |
| 2023 FY | 249.73B | 173.09B | 8.20B | 79.39B | 76.46B |
| 2024 FY | 253.22B | 177.49B | 8.59B | 82.92B | 75.56B |
| 2025 FY | 261.06B | 185.68B | 8.51B | 93.59B | 75.21B |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | 16.18B | -2.73B | 13.45B | -2.91B | 614.00M |
| 2023 FY | 13.43B | -3.03B | 10.40B | -3.13B | -4.78B |
| 2024 FY | 9.11B | -2.78B | 6.33B | -3.37B | 359.00M |
| 2025 FY | 10.64B | -2.83B | 7.81B | -3.40B | -172.00M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 122.27B | 180.05B | — | — | — |
| 2023 FY | 101.46B | 172.65B | — | — | — |
| 2024 FY | 56.52B | 130.85B | — | — | — |
| 2025 FY | 100.55B | 185.63B | — | — | — |
| 2026-12-31 | — | — | — | — | — |
| 2027-12-31 | — | — | — | — | — |
| 2028-12-31 | — | — | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q2 | 98.92B | 13.59B | 2.38B | 1.02B | 0.81 |
| 2025 Q3 | 102.87B | 13.81B | -3.21B | -3.98B | -3.13 |
| 2025 Q4 | 105.69B | 13.57B | 2.11B | 2.94B | 2.32 |
| 2026 Q1 | 100.43B | 15.62B | 4.68B | 2.94B | 2.31 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q2 | 258.34B | 180.79B | 11.79B | 82.72B | 77.38B |
| 2025 Q3 | 255.33B | 182.22B | 9.16B | 81.75B | 72.93B |
| 2025 Q4 | 261.06B | 185.68B | 8.51B | 93.59B | 75.21B |
| 2026 Q1 | 252.97B | 175.34B | 9.54B | 78.35B | 77.46B |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q2 | 1.90B | -607.00M | 1.29B | -866.00M | 1.68B |
| 2025 Q3 | 796.00M | -698.00M | 98.00M | -846.00M | -2.67B |
| 2025 Q4 | 3.39B | -784.00M | 2.61B | -845.00M | -702.00M |
| 2026 Q1 | 4.25B | -849.00M | 3.40B | -847.00M | 1.06B |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q2 | 87.33B | 158.27B | — | — | — |
| 2025 Q3 | 95.67B | 168.27B | — | — | — |
| 2025 Q4 | 100.79B | 185.87B | — | — | — |
| 2026 Q1 | 91.43B | 160.23B | — | — | — |
| 2026-06-30 | — | — | — | — | — |
| 2026-09-30 | — | — | — | — | — |
| 2026-12-31 | — | — | — | — | — |